|Budget Amount *help
¥2,200,000 (Direct Cost : ¥2,200,000)
Fiscal Year 1997 : ¥1,100,000 (Direct Cost : ¥1,100,000)
Fiscal Year 1996 : ¥1,100,000 (Direct Cost : ¥1,100,000)
We examined 40 benign prostatic hyperplasia (BPH) clinical specimens and 50 prostatic cancer clinical specimens for the expression of keraticocyte growth factor (KGF) mRNA and KGF receptor (KGF R) mRNA by using reverse transcription-polymerase chain reaction (RT-PCR). Of the BPH clinical specimens, 14(35%), 9(23%) and 3(8%) were positive for both KGF and KGF R mRNA,KGF mRNA alone and KGF R mRNA alone, respectively. Of the prostatic cancer speciments, 24(48%), 14(28%) and 6(12%) were positive for both KGF and KGF R mRNA,KGF mRNA alone and KGF R mRNA alone, respectively. Of 30 specimens of untreated prostatic cancer, 21 were positive for KGF mRNA,whereas, of 20 specimens of hormone-refractory prostatic cancer, 17 expressed the mRNA.
We also examined the clinical specimens for the localization of KGF mRNA by in situ hybridization. For the BPH specimens, a remarkable expression of KGF mRNA was found in the interstitial cells surrounding the glands, but no expression of KGF mRNA was observed in the epithelial cells.2 In 2 of 11 prostate cancer specimens examined in this study, we found the expression of KGF mRNA in the prostatic cancer cells. We have not examined the clinical specimens of the prostate for the localization of KGF receptor mRNA by in situ hybridization. In this study, we confirmed the expression of KGF mRNA and KGF R mRNA in the prostate including BPH and prostatic cancer. We also observed that KGF mRNA was localized in the interstitial cells in BPH and the mRNA was expressed in the cancer cells. These findings suggested that the paracine mechanism of KGF might play a role in the development and progression of BPH and the autocrine mechanism of KGF might contributed to pathogenesis of prostatic cancer.